For the reasons previously discussed, we stated in the CY 2026 OPPS/ASC proposed rule that we believe the use of median payer-specific negotiated charge data for a hospital's MAOs, to be collected on the Medicare cost report, may support the development of an appropriate market-based approach to payment under the Medicare FFS system by incorporating such data into the estimation of the relative hospital resources used with respect to discharges classified within a single MS-DRG compared to discharges classified within other MS-DRGs, as required by statute
La informacin, permanentemente actualizada, de todos los medicamentos autorizados y controlados por la AEMPS est disponible en la web de la Agencia, www.aemps.gob.es, dentro del apartado Centro de Informacin online de Medicamentos (CIMA)
That is why retatrutide titration is slower and more granular than tirzepatide's, and why dose-skipping carries different consequences
The creation of biosimilar drugs requires rigorous testing, analysis, and clinical trials to prove their similarity in terms of safety and efficacy to the original brand, such as Ozempic